{"name":"J Ints Bio","slug":"j-ints-bio","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE10LWphUWUwMkc4SXl1OWlBSGY2V29FNzkzSXdUUXpRbTM2MVRReWJRRjR1QWpEY2tabWl1R2kyUFlvR3BtN1R3VjBEUGl1TWxKODgxX0Z1MUNuRmswWHFrdVNVYklHOWtfeXd2bnZn?oc=5","date":"2026-02-13","type":"trial","source":"KED Global","summary":"J Ints Bio reports promising early trial findings against lung cancer resistance mutation - KED Global","headline":"J Ints Bio reports promising early trial findings against lung cancer resistance mutation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxPUFhfUm5HWlh3Um1xVmMzOFJrRmd0WExOdy1IaGhBakVVZHNkaUJpZjk0eEF2SUNFTUVBY2Y2aWRrcWZ4M2pCTlk5MnhzSTE2cGNKUGhSQlhxejJvcWpqU3p0QlItSjZlUkZqY2E2YjZQak9XUUFHaXZNQ2d6cEF5NTVJWHc3dnZ2SS15YnBzUFJwZVVrekpTMExNRzVxUDQ?oc=5","date":"2026-02-12","type":"pipeline","source":"PharmTech.com","summary":"JIN-A02 Overcomes Tagrisso Resistance via C797S and T790M Targeting - PharmTech.com","headline":"JIN-A02 Overcomes Tagrisso Resistance via C797S and T790M Targeting","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxNNWZqR2lKa0dRMHZKbWRnN05DNHNCODdEV2FvWUcwZjA0RW1kQktpekFCeVBCVXhjQWtHR2FqMlJtUkVVY012NE1SSEw4NXVHVjBKSmVUYnJnNWplRFh2VWJIaUgydi00ejlRTjF4SVVqQTdvZ0FTN3lyU3Y0QURtUTNXdmpDbFVoTm50dzY4aTloNFQ3Y3dsQVlaY0N1dHVYV01IV3lkWEo5NzZnd1RTNmlCektObjNHSGhmOV9BLWZVa3FSelg3Y2hzU1FoSlVnY2N5WDhR?oc=5","date":"2026-02-12","type":"pipeline","source":"PR Newswire Asia","summary":"J INTS BIO Reports Fourth-Generation EGFR Inhibitor JIN-A02 in Clinical Cancer Research - PR Newswire Asia","headline":"J INTS BIO Reports Fourth-Generation EGFR Inhibitor JIN-A02 in Clinical Cancer Research","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-wFBVV95cUxOME0xQkhsQlFwQ2JObzFQcm1TMDItNWFqMDNSdk10eWtFQWRXTGJJekJnNkJleFV2ZF9kN1dXUzhFU0xfWFRmTVJnM2hxdFhUWFhFUmlMZWZZSjVwU3hvWHRuWXAtUy16aG0wLTNfMjhpbndQX0xrdUY3T3dWNUw2ZGtyVzJ5d0hQODhNVnQ2RGx6ZHRXTW5nSm81NDRwd09sV3BqRmUzNThoUUs1OFhXSUEyOFhhZUE5LXJxN0wyWmxjT3dIZEx3Z1FoOFg4OHZGNklSUWpSbk5BUVJKMEV4UTRlT3l4czMwQzdpZExZTjRHdlY5Z0FLNlBwWQ?oc=5","date":"2026-02-11","type":"pipeline","source":"prnewswire.com","summary":"EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight - prnewswire.com","headline":"EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFA3UjkwekNBY1RiaXZldjdMVDNzUUVIaE1qRW9OSXRwbGlDcU5QVFdMX1dFTDhZazN4STd6RW1qa0dKV19wZGlSdmU3dFp1NW52WFVaRnp5dUxCOUFudU5sSkhxcGJTbmpvcFVROXh3?oc=5","date":"2025-09-11","type":"pipeline","source":"KED Global","summary":"J Ints Bio unveils 4th-generation targeted anti-cancer drug candidate - KED Global","headline":"J Ints Bio unveils 4th-generation targeted anti-cancer drug candidate","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxPdmJzRmJ5UU9iUmg4UkYwNWhNS1BpWGI4VkpyUkZ0bnFOOS0zbTBacVJTVUFBaTRZUFNQVDZseEdiWEFJWVotbjlRZXd1ZWVKMkZaMUthbXA2UVdyQVZUY0xtLUtuWFlMSkhvbVdJT0RzWXYzSEdKUVZ3bmlvN0xrTVRB?oc=5","date":"2025-05-01","type":"pipeline","source":"BioSpectrum Asia","summary":"The Rise of K-Biotech - BioSpectrum Asia","headline":"The Rise of K-Biotech","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAJBVV95cUxPbHNWTFFUMjNvVmVQR0lqX1FCSGVvSlItWDBwLXB1d1h6SjZqdHYwaXFZaThiVEx1aTZyZnVRWG5rTHJORHQzcjNJR21wcXJtSDMwSkV2akliVXcxVjNSc05JMlRlcG5kRHFBbU4zeFF2ZVcyOHF1QlJsY3FydW9qSE5ia2hOb3N1blJNckt0bHk1aWNyMEFPNkVJUWZCaEV3N205TE5va3JkXzluMUJoUVVsZThGTWtVenRVWTZOcVNxZ0FVY1d4S3c2MEw3VWVUMzBjcnFVZVkxX0Q4NkRGeEt6a2hVNjNQSFJKWFdlWW1ObjJtd25kcjZ2emZCUUljQ2FtR3hNRi1ZalBq?oc=5","date":"2025-04-30","type":"pipeline","source":"prnewswire.com","summary":"J INTS BIO Presents Research Results for Next-Generation Innovative Anticancer Therapeutics 'JIN-A02' and 'JIN-001' at AACR 2025 - prnewswire.com","headline":"J INTS BIO Presents Research Results for Next-Generation Innovative Anticancer Therapeutics 'JIN-A02' and 'JIN-001' at A","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwJBVV95cUxQRG5ndW1nZi1xSnFQcDYtdUdFU3l0dGtOWkFqVE5sNTBid00zSDJncUptcER1TEdleHZwTUpxODVENXJNWnd2Vzh0bm1fdEpwZWl0bmlod2I4WDlPdzIxSmdTMzhuMThOeERuN3BEMmlEN3I0YUJ0SjVXbDA4dEJ2dGNXeTUzVGl2VUlPNmR0cjBzLWlZVUFnSmVhVGY0VzVYVnFueDRaUzlEbjdyOThlX0FjQUcwX1paWDFYR0xOX2NlM1FKRTg3SHRTVExxb1NXbUpCVWtNQWhxX0R2ZjlaTHZDRERxbEdvNEUtQkhqc0JlUDR1djRjWWx3UnhSeVBjRWwtbGx6RQ?oc=5","date":"2024-11-25","type":"pipeline","source":"BioSpace","summary":"J INTS BIO and MD Anderson Collaborate on the Development of Brain Tumor Treatment 'JIN-001' - Enhancing Radiation and Chemotherapy Efficacy - BioSpace","headline":"J INTS BIO and MD Anderson Collaborate on the Development of Brain Tumor Treatment 'JIN-001' - Enhancing Radiation and C","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxQaDFLQ0FVTnN5TWNNcEpfZW5YZ3dlLWFTUWN4aEd1S2s2NEg0NmotRHBkOHFBVl9XOExxY1ZoWU5CcmMyVlBlOG51RXVkcF83dWtaSFpNVXJpYzh3RG5sNmVFR3JXQTNzSGEzVGVsMmV4M2MxQ05KRWVZdGhyelo2RWh4VkZqb1NJcjFoUW9zS1ZDNHZLenpXNk1QelFtTnZLTVJrTm5GLXIxVE5mNHc?oc=5","date":"2023-09-26","type":"pipeline","source":"Oncology Pipeline","summary":"Bridge mirrors Black Diamond and Blueprint’s search for something better - Oncology Pipeline","headline":"Bridge mirrors Black Diamond and Blueprint’s search for something better","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxPTEpWd3l4VkVLOXJZSlhzUEdnUkRqTDVCUEJCclVmOHJ4UDJKaUl4Q3VDYjVrTS1UOWdEcjVIeUs0T29zbEduVnFTbEhVLWFXZHVKUHBHWWI2UnBIWWJkSXNKaGwwcWI2R1NOSW1CbFF0V0ZPaGM2dXoxaXZ5UDB1TnN1WnRacVlNMzdSWkdZVVNSc3p2UGlNRXV3N1JfMmdLSzNNXw?oc=5","date":"2023-07-31","type":"trial","source":"Clinical Trials Arena","summary":"First patient dosed in Phase I/II trial of JIN-AO2 for NSCLC - Clinical Trials Arena","headline":"First patient dosed in Phase I/II trial of JIN-AO2 for NSCLC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxPaEVwd1VKRmtvNkRkOTdwWm5vdDNRVXFKQ1FsN0xSX09kenhjclNENkVNSkhMZWNoWjRwX2trSDRsVmRDTDZJdjJZU3llaURnZUFwcG5oQk94LXB4c3cteFhLc0h6RGt0bnZUUlhnVUlnTHgzaEY3TEJ4cEdpUzBERjFJVXVEb1hXa3FHRzRwbURPZnRRSUNiaTU5eXlTcjctN2VJeXREQ3Z2cFRNRm5zMDZQaUptVFFabUgxZkFwZGc?oc=5","date":"2023-06-02","type":"deal","source":"Fierce Pharma","summary":"Fierce Pharma Asia—Sun's Taro buyout; Eli Lilly's XtalPi collab; Yuhan's cancer candidate - Fierce Pharma","headline":"Fierce Pharma Asia—Sun's Taro buyout; Eli Lilly's XtalPi collab; Yuhan's cancer candidate","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBtVElBaU1mVXZPOUNObVRrYjZ1SjZFa1YwMWZocEJvMmFSejBuMjE2ekhmWUs2NlFnX3o1alE0Y0FRRVdOVnJrZ3ZGN3VnXzdkVlBpTUVwakZoa2xPVkRVQlNQbkRiU3poNGxkTjJ30gFyQVVfeXFMTVJGWkxzT00yRkRlSVJmYU5vSWxRTE5fa0hpUEQweFhfeXdyVXFWODNqRl9BYUROR0xaUWRZQTd5M1BoZHBXMi0xa3lRV0o2dVhoNzJKdnU1UENLXzc1MlcxbWpuSGRsVGlHYWZPcF9ZTGR3?oc=5","date":"2023-06-01","type":"deal","source":"koreabiomed.com","summary":"Yuhan acquires J INTS BIO’s TKI to develop first-in-class NSCLC drug - koreabiomed.com","headline":"Yuhan acquires J INTS BIO’s TKI to develop first-in-class NSCLC drug","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}